Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vegf-siRNA lentivirus
- Development stage
- Preclinical
- Lead developer
- Renji Hospital
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
VEGF-siRNA lentivirus refers to a gene therapy approach that utilizes a lentiviral vector to deliver small interfering RNA (siRNA) or short hairpin RNA (shRNA) molecules. These RNA molecules are designed to specifically target and silence the expression of Vascular Endothelial Growth Factor (VEGF) through RNA interference (RNAi). By reducing VEGF protein levels, this therapeutic strategy aims to inhibit angiogenesis (the formation of new blood vessels), thereby suppressing tumor growth and metastasis in various cancers, and preventing neovascularization in ocular pathologies. This approach is primarily in the research and pre-clinical stages of development.
- Other names
- Lentivirus-mediated VEGF-C siRNALentivirus-mediated siRNA targeting VEGFVEGF-shRNA lentivirus
02
Targets
G4 (G-quadruplex DNA)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on vegf-siRNA lentivirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vegf-siRNA lentivirus.